Kovaleski Elenara Simoni, Schroeder Helena, Krause Mauricio, Dani Caroline, Bock Patrícia Martins
Centro Universitário Metodista IPA, Porto Alegre, RS, Brasil.
Universidade Federal de Ciências da Saúde de Porto Alegre - UFCSPA, Porto Alegre, RS, Brasil.
J Vasc Bras. 2016 Jul-Sep;15(3):182-188. doi: 10.1590/1677-5449.002016.
Obesity can be associated with diseases such as diabetes, arterial hypertension and dyslipidemia. Bariatric surgery is one of the most effective treatments available, reducing both weight and comorbidities.
To evaluate the metabolic and pharmacotherapeutic profile of obese patients after bariatric surgery.
This is a retrospective, cross-sectional, observational study conducted at a hospital located in the city of Porto Alegre, RS, Brazil, based on analysis of the medical records for 70 patients who underwent bariatric surgery covering periods spanning from 2 months prior to more than 6 months after their bariatric surgery. Statistical analysis was conducted using SPSS 17.0®.
Initial arterial blood pressure was 130/85 mmHg, 6 months after surgery it was 120/80 mmHg (p < 0.01). The metabolic profile 2 months before surgery was as follows: HDL was 34 mg/dL, total cholesterol was 195.07 ± 40.17 mg/dL, LDL was 118.22 ± 41.28 mg/dL, triglycerides were 141.09 ± 43.39 mg/dL, and fasting glycemia was 90 mg/dL. The same figures 6 months after surgery were 43 mg/dL, 133.67 ± 28.14 mg/dL, 65.53 ± 24.3 mg/dL, 104.41 ± 29.6 mg/dL, and 77 mg/dL, respectively (p < 0.01). Use of medications 2 months before surgery was as follows: 41% were on antihypertensives, 39% on hypolipidemics, 10% on oral hypoglycemics, and 97% were on nutritional supplements. These percentages 6 months after surgery had changed to 21%, 19%, 9% and 99%, respectively.
This study illustrates that bariatric surgery for obese patients with comorbidities was successful, demonstrating improvements in their metabolic profile and reductions in use of medications used to treat comorbidities.
肥胖可能与糖尿病、动脉高血压和血脂异常等疾病相关。减肥手术是现有的最有效治疗方法之一，可减轻体重并降低合并症的发生率。
评估肥胖患者减肥手术后的代谢和药物治疗情况。
这是一项在巴西里约热内卢阿雷格里港市一家医院进行的回顾性、横断面观察性研究，基于对70例接受减肥手术患者的病历分析，时间跨度从减肥手术前2个月至术后6个月以上。使用SPSS 17.0®进行统计分析。
初始动脉血压为130/85 mmHg，术后6个月为120/80 mmHg（p < 0.01）。手术前2个月的代谢情况如下：高密度脂蛋白（HDL）为34 mg/dL，总胆固醇为195.07±40.17 mg/dL，低密度脂蛋白（LDL）为118.22±41.28 mg/dL，甘油三酯为141.09±43.39 mg/dL，空腹血糖为90 mg/dL。术后6个月的相应数据分别为43 mg/dL、133.67±28.14 mg/dL、65.53±24.3 mg/dL、104.41±29.6 mg/dL和77 mg/dL（p < 0.01）。手术前2个月的用药情况如下：41%服用抗高血压药，39%服用降血脂药，10%服用口服降糖药，97%服用营养补充剂。术后6个月这些百分比分别变为21%、19%、9%和99%。
本研究表明，对患有合并症的肥胖患者进行减肥手术是成功的，其代谢情况得到改善，用于治疗合并症的药物使用量减少。
